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Aims and method An ‘assertive approach’ to clozapine, where nasogastric
administration is approved, is assessed through a case-load analysis to provide the
ﬁrst systematic description of its use and outcomes worldwide.
Results Five of the most extremely ill patients with treatment-resistant
schizophrenia were established and/or maintained on clozapine, resulting in
improvements to their mental state; incidents were reduced, segregation was
terminated and progression to less restrictive environments was achieved.
Clinical implications Despite being underutilised and rarely enforced, in extreme
circumstances, an assertive approach to clozapine can be justiﬁed. Nasogastric
clozapine can be safely delivered and the approach itself, rather than actual
nasogastric administration, may be enough to help establish and maintain patients
with treatment-resistant schizophrenia on the most eﬀective treatment.
Declaration of interest E.S. has received speaker fees from Jansen Pharmaceuticals
and Novartis.
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The eﬃcacy of clozapine in treatment-resistant schizophre-
nia is well established.1 Compared with alternative antipsy-
chotics, clozapine provides superior symptom control,
longer duration of treatment, shorter lengths of stay and
reduces violence.2 Although enforced antipsychotic treat-
ment is generally widespread, clozapine is both underuti-
lised3 and rarely enforced, with only a handful of case
reports worldwide reporting the use of nasogastric4–6 and
intramuscular7–9 clozapine.
With injectable clozapine unavailable in the UK until very
recently, when presented with a crisis,10 nasogastric clozapine
was successfully used for the ﬁrst time at Ashworth high-
security hospital in 2010 and has been used subsequently to
help establish and maintain treatment with clozapine. We
now present the ﬁrst systematic description of the ‘assertive
approach’ to clozapine via nasogastric clozapine, which com-
mences not on the ﬁrst administration of nasogastric clozapine,
but on its approval for use; this in itself is often enough.
Methods
A retrospective case-load analysis of E.S.’s patients was con-
ducted on an intent-to-treat basis, deﬁned by the presence of
a Second Opinion Appointed Doctor (SOAD) request for the
authorisation of nasogastric clozapine, from the ﬁrst case in
2010 through to 2016. This provided a minimum 12-month
follow-up period. Clinical records were reviewed to identify
patient demographics and clinical details including medica-
tion compliance and response to treatment, which was deter-
mined by Clinical Global Impression (CGI) scores11 combined
with segregation use and incident frequency for 12 months
before and after SOAD approval for nasogastric clozapine.
The method used to deliver nasogastric clozapine is out-
lined within Box 1.
Results
E.S. had cared for ﬁve patients, whose demographics can be
seen in Table 1, where a SOAD approved the administration
of clozapine via a nasogastric tube. All were diagnosed with
treatment-resistant schizophrenia (ICD-10 code F2012), all
were conﬁned in their rooms because of risk to others (long-
term segregation13) and all were considered to be among the
most extremely ill patients encountered within this particu-
lar population (CGI score of 7 for severity of illness).
For all patients, their families, advocates and/or legal
team were consulted. None objected.
At the time the assertive approach to clozapine was
initiated (i.e. SOAD approval for its use was gained), two
patients had not started clozapine and three patients had
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started clozapine but were not reliably compliant (median
duration of 31 days); ultimately, only three patients received
nasogastric clozapine and other than the use of restraint, no
adverse incidents occurred.
Patient 1 commenced clozapine after SOAD approval
and received four doses of nasogastric clozapine on non-con-
secutive occasions over a period of 3 weeks, before being
established on oral clozapine. Patient 2 only commenced
oral clozapine after SOAD approval for nasogastric cloza-
pine, but nasogastric administration itself was never
required. Patient 3 commenced oral clozapine after persua-
sion, but threatened to stop and SOAD approval was enough
to maintain compliance without nasogastric administration
being necessary. Patient 4 took oral clozapine for 1 month
Table 1 Patient demographics
Patient
Age at ﬁrst
episode of
psychosis
Age at
admission to
high-security
services
Age at SOAD
approval of
nasogastric
clozapine
Duration of
illness at
SOAD approval
of nasogastric
clozapine
Length of stay in
high-security
services at SOAD
approval of
nasogastric
clozapine
Primary
diagnosis Admission source
Mental
Health Act
section on
admission
1 19 43 43 24 98 days F20.3 Medium-security
hospital
3
2 21 27 43 22 16 years F20.0 Prison 47/49
3 21 33 35 14 2 years F20.0 Prison 47/49
4 19 39 45 26 5 years F20.0 Medium-security
hospital
37/41
5 15 25 33 18 8 years F20.3 Medium-security
hospital
3
Age and duration of illness is presented in years. Primary diagnosis is given by ICD-10 code (see ICD-10 for full deﬁnitions). SOAD, Second Opinion Appointed Doctor.
Box 1. How to deliver nasogastric clozapine.
Clozapine preparation
Although several brands of clozapine are available and unlicensed ‘special’ oral suspensions can be prepared (including crushed tablets), we
advocate the use of Denzapine as this is currently the only licensed oral suspension in the UK. If an alternate clozapine provider is currently in
operation, then registration of the hospital and prescribing psychiatrist with a second supplier are necessary before transferring the patient’s
registration. This risks using two clozapine monitoring systems in one hospital, with possible confusion regarding dispensing medication and
liaising with different clozapine-monitoring services as well as the potential of having to switch providers once the patient is established on
tablet medication.
Restraint
A thorough risk assessment is required to ensure adequate numbers of trained, competent and resilient staff are present and it is essential
they are well supported by the leadership team; consultant presence was initially provided, being replaced by more junior medical staff when
confidence grew. At least one member of Resus Council (UK) ‘Immediate Life Support’ trained member of staff must be present. Throughout
every intervention, patients should be repeatedly given the option of taking oral clozapine. Mechanical restraint was considered as an option but,
even with our most difficult patients, was neither planned nor used. Manual restraint was sufficient with between two and six members of staff;
in the most extreme cases one member of staff was allocated to each limb, with two controlling the head. Patients were usually seated upright on
the edge of their bed, with their neck in line with their back. Precautions may be required to mitigate risks of spitting and biting, including
lightweight disposable face visors and gloves.
Nasogastric tube placement
Appropriate training for both medical and nursing staff can be arranged with a general hospital clinical skills team. Fine bore feeding tubes
should be used. The first-line, gold-standard method of confirming placement in the stomach is by demonstrating a gastric pH of ≤5.5.14
Acid-inhibiting medication reduces the sensitivity but does not alter the specificity or render the method unsafe14; actions to reduce this risk
should be considered. Radiological confirmation is not required.14 Once placement is confirmed, nursing staff can administer the clozapine,
which varies in volume (50 mg/ml) throughout titration. Unless safe to leave in situ, the nasogastric tube should be removed immediately after
clozapine administration.
Legal authority
In England and Wales, incapacitous or non-consenting patients detained under the Mental Health Act 1983 may be administered drug
treatments for mental disorders for longer than 3 months only if a Second Opinion Appointed Doctor (SOAD) approves the treatment, including
the route of administration. Personal communication from the principal SOAD has indicated that the oral and nasogastric routes are equivalent:
both are enteral.
Ethical dilemmas
Explored by Silva et al10, there are ethical dilemmas with administering nasogastric clozapine. These involve balancing the risks and benefits of
an unacceptable status quo against the uncertainties of the possible risks and benefits of intervention, alongside containing and resolving the
emotions of the team when using a novel, restrictive and coercive treatment on a vulnerable and incapacitous patient.
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but then repeatedly threatened to refuse. SOAD approval
was sought and nasogastric clozapine was administered
once, which was enough to maintain compliance thereafter.
Patient 5 maintained erratic compliance with oral clozapine
and despite taking it for 617 days, was approved for nasogas-
tric clozapine because of life-threatening clozapine with-
drawal catatonia that had previously been unresponsive to
benzodiazepines or electroconvulsive therapy (ECT). In the
12 months after SOAD approval for nasogastric clozapine,
he received it four times on non-consecutive occasions
over the ﬁrst 6 months.
All ﬁve patients were considered to have shown a global
improvement on CGI scores after the initiation of an assert-
ive approach to clozapine, with the drug eﬃcacy index show-
ing that, for the majority of patients, clozapine had resulted
in a ‘vast’ or ‘decided’ improvement in their condition
(Table 2). Across all ﬁve patients, incidents reduced from
an average of 72 over the 12 months before SOAD approval
to 29 in the 12 months after SOAD approval. No patients
were unchanged or worse, and only patient 5 remained in
segregation beyond 12 months (terminated on the 476th
day). Therefore, despite a signiﬁcant reduction in incidents
(Fig. 1), they were registered as having only minimally
improved according to their CGI score.
Our most recent data (with a minimum follow-up of
2 years after SOAD approval for nasogastric clozapine)
demonstrates that none of the ﬁve patients required cloza-
pine re-titration, and that all are now compliant with cloza-
pine (although patient 5 did require a nasogastric tube to be
passed on one occasion before accepting clozapine orally
nearly 2 years (626 days) after it was last administered
nasogastrically).
Discussion
The majority of patients are transferred to high-security
hospitals in the UK because the severity of their psychotic-
ally driven violence is considered to be uncontainable else-
where, and a large proportion of the patient population
already complies with clozapine without using what we
can only describe as a highly assertive approach.15 This is
reserved for those with the most severe and debilitating
conditions. They have often been detained for decades,
with some spending years in segregation despite persistent
attempts at engagement in psychological work and/or numer-
ous trials of both evidence-based and/or other none or weakly
evidence-based treatments (including failed attempts on
clozapine secondary to poor compliance), commonly includ-
ing treatment with high-dose and/or multiple antipsycho-
tics, which are both unlikely to work and hazardous to the
individual.16,17
Although all health professionals prefer to initiate treat-
mentswith patientswho fully understand and actively consent
and cooperate, in these rare cases, the status quo is clearly
unacceptable and the ethical argument for this very assertive
approach to clozapine, once conceived of, is not hard to make
to establish and maintain patients on clozapine.10
However, a survey of psychiatrists working in psychi-
atric intensive care units in the UK found that even restraint
to take bloods for clozapine was very rarely reported and
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attitudes towards it were variable, with a signiﬁcant minority
describing it as never appropriate.18 The same author’s
description of an approach to enforcing clozapine, including
taking bloods in restraint,19 resulted in critical responses:
one expressing dismay that the article was published at
all,20 and the other setting out why it would not work.21
Our results demonstrate that simply accepting refusal of
clozapine from a patient with treatment-resistant schizo-
phrenia can deprive them of the beneﬁts that this
signiﬁcantly superior (compared with all other antipsycho-
tics22) and recommended treatment of choice provides,
and how an assertive approach to clozapine, rather than
actual nasogastric administration, can help initiate and
maintain treatment leading to improvements in mental
state, reductions in incidents, terminations of seclusion
and transfers to less restrictive environments.
These results were not unexpected, given the unique
properties of clozapine on treatment-resistant schizophrenia
and violence.2 Neither was the sometimes signiﬁcant period
of decompression before segregation was stopped, as despite
some patients having a rapid improvement and almost
immediate cessation of incidents of aggression or violence,
they had signiﬁcant histories of being involved in dramatic
and disabling assaults against staﬀ and therefore extreme
caution was exercised.
What was clinically unexpected, given the individual
patient histories, was the surprising level of cooperation.
There were fewer restraints and enforced nasogastric cloza-
pine administrations than had been expected, and one
patient who had repeatedly refused oral clozapine for
years cooperated without nasogastric administration at all,
although this was also a ﬁnding when intramuscular cloza-
pine was enforced in the Netherlands.23
It is possible that teams redoubled their eﬀorts, that
patients were aware of the possibility of restraint and were
coerced by the prospect alone or that patients regained a
level of insight, or even a combination of the three; it is
diﬃcult to tell.
As Silva et al10 discuss, teams that embark on this
approach are faced with very diﬃcult decision-making,
such as how long to persist with one attempt at passing a
nasogastric tube? When is a patient’s distress at the proced-
ure too great? And how many times should clozapine be
administered via a nasogastric tube before accepting that
oral compliance will not be maintained? These questions
are not easy to answer, and the judgements can only be
made by individual teams and will vary on their own cap-
acity to maintain treatment and a relationship with a patient
in very diﬃcult circumstances.
For some patients their previous refusals will be based
on psychotic motivations and it is hoped that these patients
may quite rapidly respond. Others may have a combination
of psychotic, personal and possibly comorbid motivations
that may not be remedied by either clozapine or this assert-
ive approach. For these patients, we would not advocate the
regular use of nasogastric administration of clozapine as a
long-term solution. We know, particularly when huge eﬀort
and resources are expended on initiatives, that there can be
a tendency to get stuck in a persisting course of action or to
fail to consider alternative approaches24 (although in this
case many of these are less likely to work22), and teams
must be careful not to fall into this trap.
One good alternative, with local guidelines emerging,25
is the option of trying to establish patients on clozapine
by an assertive approach with intramuscular injections.
Having recently become available again, intramuscular clo-
zapine may be preferred to nasogastric clozapine, given the
less intrusive and unpleasant method of administration.
However, unlike nasogastric clozapine, intramuscular cloza-
pine is limited by the deliverable dose and therefore dur-
ation of treatment, with large volumes required (25 mg/
ml) as the titration increases toward the average UK dosage
of around 450 mg/day.26 Intramuscular clozapine also
remains an unlicensed product, with an increased likelihood
of prone restraint and a theoretical risk of accidental intra-
venous administration. Therefore, although intramuscular
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clozapine provides an additional treatment option, nasogas-
tric clozapine can continue to have an important role to pre-
vent re-titration and administer clozapine when the
maximum deliverable dose of intramuscular clozapine is
insuﬃcient.
Another alternative, where an assertive approach to clo-
zapine fails or for the signiﬁcant number of patients who do
not respond to clozapine monotherapy or clozapine augmen-
tation strategies, is the more restrictive treatment of ECT,
which may well be the most appropriate next step.27
However, for the cohort we describe, this intervention is
particularly diﬃcult to deliver and maintain the safety of
both staﬀ and patients.
Ethically, what remains is a real argument about the
wrongs of a failure to treat the most severely ill patients
with treatment-resistant schizophrenia against the per-
ceived wrongs of nasogastric clozapine. Clearly, this
approach can never be a panacea: clozapine can often not
be used (because of adverse eﬀects) and nearly 50% of
patients fail to achieve a satisfactory therapeutic response.28
However, for those who have suﬀered with the most debili-
tating conditions imaginable, clozapine can result in dra-
matic and seemingly unexpected improvements in mental
state and function. Accepting a patient’s refusal of treatment
and failing to oﬀer them that chance of improvement via an
assertive approach to clozapine through nasogastric admin-
istration seems, in our opinion, cruel and unnecessary.
Conclusion
Our case series shows that nasogastric clozapine can be safely
delivered and that the approach itself, rather than actual
nasogastric administration, may be enough to establish and
maintain treatment with clozapine.
An assertive approach to clozapine can therefore play
an important role in managing patients with treatment-resist-
ant schizophrenia. It can be justiﬁed to help reduce patients’
extreme suﬀering and distress as a result of their psychosis,
can be expanded in a variety of psychiatric in-patient settings
and can help reduce the usually disappointing outcomes seen
with other drugs or drug combinations.
This is the ﬁrst systematic description of the assertive
approach to clozapine and helps counter likely objections
regarding the eﬃcacy and risk of administering nasogastric
clozapine that might otherwise prevent or delay patients
with treatment-resistant schizophrenia receiving the recom-
mended treatment of choice.
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